Tyra Biosciences, Inc. 4

RA Capital Management, L.P. and affiliated entities reported an award of stock options for 13,160 shares of Tyra Biosciences, Inc. common stock at a $32.68 exercise price in connection with director compensation.

On May 28, 2026, RA Capital Management, L.P. and affiliated reporting persons reported the award of a stock option covering 13,160 shares of Tyra Biosciences, Inc. common stock at an exercise price of $32.68 per share, granted under the issuer’s Non-Employee Director Compensation Program in connection with Dr. Jake Simson’s service on the board. The option vests in 12 equal monthly installments following the grant date, with any remaining unvested portion accelerating at the next annual shareholder meeting if it occurs within one year, contingent on Simson’s continued service. The reporting persons state that, under an arrangement with RA Capital, Simson holds the option for the benefit of RA Capital Healthcare Fund, L.P., RA Capital Nexus Fund, L.P., and a separately managed account, and that any net cash or stock from exercise will be turned over to the adviser to offset advisory fees, and they therefore disclaim beneficial ownership beyond any pecuniary interest. Following this award, 13,160 option shares are reported as indirectly owned, with an implied notional value of about $430,000 based on the exercise price.

Filing Facts

CIK

1863127

Ticker

TYRA

Form

4

Source Type

sec

Accession

0001231919-26-000590

Alert Tier

5